A longitudinal real-life comparison study of natalizumab and fingolimod-Reference-Cited by-同舟云学术

A longitudinal real-life comparison study of natalizumab and fingolimod

Published:2016-12-15 Issue:3 Volume:136 Page:217-222
ISSN:0001-6314
Container-title:Acta Neurologica Scandinavica
language:en
Short-container-title:Acta Neurol Scand

Author:

Lanzillo R.¹,Carotenuto A.¹,Moccia M.¹,Saccà F.¹,Russo C. V.¹,Massarelli M.¹,De Rosa A.¹,Brescia Morra V.¹

Affiliation:

1. Department of Neurosciences, Reproductive and Odontostomatological Sciences; Multiple Sclerosis Clinical Care and Research Centre; Federico II University; Naples Italy

Publisher

Wiley

Subject

Clinical Neurology,Neurology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ane.12718/fullpdf

Reference28 articles.

1. The immune modulator FTY720 targets sphingosine 1-phosphate receptors;Brinkmann;J Biol Chem,2002

2. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis;Kappos;N Engl J Med,2010

3. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis;Cohen;N Engl J Med,2010

4. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial;Calabresi;Lancet Neurol,2014

5. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis;Polman;N Engl J Med,2006

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod;Journal of Neurology;2024-08-23

2. A two-years real-word study with fingolimod: early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression;Frontiers in Immunology;2024-06-07

3. Do efficacy results obtained from randomized controlled trials translate to effectiveness data from observational studies for relapsing–remitting multiple sclerosis?;Pharmacoepidemiology and Drug Safety;2024-05

4. Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity;Multiple Sclerosis and Related Disorders;2023-02

5. Disease-modifying drugs for multiple sclerosis and subsequent health service use;Multiple Sclerosis Journal;2021-12-24